Edwards Lifesciences market cap is $71.4 b, and annual revenue was $4.39 b in FY 2020

Edwards Lifesciences Gross profit (Q2, 2021)1 B

Edwards Lifesciences Gross profit margin (Q2, 2021), %75.7%

Edwards Lifesciences Net income (Q2, 2021)489.5 M

Edwards Lifesciences EBIT (Q2, 2021)542.1 M

Edwards Lifesciences Cash, 30-Jun-20211.3 B

Edwards Lifesciences EV70.7 B

Edwards Lifesciences revenue was $4.39 b in FY, 2020 which is a 0.9% year over year increase from the previous period.

Edwards Lifesciences revenue breakdown by business segment: 16.5% from Critical Care, 17.4% from Surgical Structural Heart, 65.1% from Transcatheter Aortic Valve Replacement and 1.0% from Other

Edwards Lifesciences revenue breakdown by geographic segment: 9.9% from Rest of World, 10.5% from Japan, 22.2% from Europe and 57.4% from United States

USD | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|

## Revenue | 3.7b | 4.3b | 4.4b |

| 8% | 17% | 1% |

## Cost of goods sold | 939.4m | 1.1b | 1.1b |

## Gross profit | 2.8b | 3.2b | 3.3b |

| 75% | 74% | 75% |

## R&D expense | 622.2m | 752.7m | 760.7m |

## General and administrative expense | 1.1b | 1.2b | 1.2b |

## Operating expense total | 2.0b | 2.1b | 2.4b |

## EBIT | 748.2m | 1.1b | 897.6m |

| 20% | 26% | 20% |

## Interest expense | 29.9m | 20.7m | 15.8m |

## Interest income | 32.0m | 32.2m | 23.4m |

## Pre tax profit | 761.4m | 1.2b | 916.7m |

## Income tax expense | 39.2m | 119.6m | 93.3m |

## Net Income | 722.2m | 1.0b | 823.4m |

## EPS | 3.4 | 4.9 | 1.3 |

USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 |
---|---|---|---|---|---|---|---|---|

## Revenue | 993.0m | 1.1b | 1.1b | 1.1b | 925.0m | 1.1b | 1.2b | 1.4b |

## Cost of goods sold | 231.8m | 304.0m | 292.4m | 265.1m | 238.2m | 281.0m | 293.4m | 334.3m |

## Gross profit | 761.2m | 782.9m | 801.6m | 863.6m | 686.8m | 859.9m | 923.2m | 1.0b |

| 77% | 72% | 73% | 77% | 74% | 75% | 76% | 76% |

## R&D expense | 171.4m | 191.9m | 195.5m | 187.4m | 182.1m | 195.5m | 207.0m | 225.3m |

## General and administrative expense | 280.3m | 308.5m | 306.2m | 307.8m | 274.9m | 307.2m | 330.8m | 374.5m |

## Operating expense total | 487.0m | 515.4m | 507.3m | 505.5m | 856.5m | 502.1m | 539.7m | 499.6m |

## EBIT | 274.2m | 267.5m | 294.3m | 358.1m | (169.7m) | 357.8m | 383.5m | 542.1m |

| 28% | 25% | 27% | 32% | (18%) | 31% | 32% | 39% |

## Interest expense | 1.0m | |||||||

## Pre tax profit | 278.0m | 271.3m | 301.7m | 364.5m | (168.2m) | 364.3m | 389.3m | 545.5m |

## Income tax expense | 28.3m | 29.0m | 27.0m | 53.9m | (46.3m) | 39.1m | 51.1m | 56.0m |

## Net Income | 249.7m | 242.3m | 274.7m | 310.6m | (121.9m) | 325.2m | 338.2m | 489.5m |

## EPS | 1.2 | 1.1 | 1.3 | 1.5 | (0.2) | 0.5 | 0.5 | 0.8 |

USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Cash | 818.3m | 714.1m | 1.2b | 1.2b |

## Accounts Receivable | 421.6m | 456.9m | 543.6m | 514.6m |

## Prepaid Expenses | 60.6m | 54.3m | 59.1m | 75.1m |

## Inventories | 554.9m | 607.0m | 640.9m | 802.3m |

## Current Assets | 2.5b | 2.3b | 3.0b | 3.1b |

## PP&E | 679.7m | 867.5m | 1.1b | 1.4b |

## Goodwill | 1.1b | 1.1b | 1.2b | 1.2b |

## Total Assets | 5.7b | 5.3b | 6.5b | 7.2b |

## Accounts Payable | 116.6m | 134.0m | 180.4m | 196.5m |

## Short-term debt | 636.6m | 25.5m | 27.2m | |

## Current Liabilities | 1.4b | 876.6m | 902.4m | 893.9m |

## Long-term debt | 438.4m | 593.8m | 653.3m | 667.7m |

## Total Debt | 1.1b | 593.8m | 678.8m | 694.9m |

## Common Stock | 212.0m | 215.2m | 218.1m | 636.4m |

## Additional Paid-in Capital | 1.2b | 1.4b | 1.6b | 1.4b |

## Retained Earnings | 2.0b | 2.7b | 3.7b | 4.6b |

## Total Equity | 3.0b | 3.1b | 4.1b | 4.6b |

## Debt to Equity Ratio | 0.4 x | 0.2 x | 0.2 x | 0.2 x |

## Debt to Assets Ratio | 0.2 x | 0.1 x | 0.1 x | 0.1 x |

## Financial Leverage | 1.9 x | 1.7 x | 1.6 x | 1.6 x |

USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Net Income | 583.6m | 722.2m | 1.0b | 823.4m |

## Depreciation and Amortization | 81.9m | 77.4m | 89.3m | 107.2m |

## Accounts Receivable | (3.9m) | (28.7m) | (88.0m) | 41.9m |

## Inventories | (124.0m) | (65.7m) | (105.4m) | (120.6m) |

## Accounts Payable | 85.2m | 192.5m | (63.5m) | (84.5m) |

## Cash From Operating Activities | 1.0b | 926.8m | 1.2b | 1.1b |

## Purchases of PP&E | (168.1m) | (238.7m) | (254.4m) | (407.0m) |

## Cash From Investing Activities | (647.2m) | 76.7m | (595.8m) | (531.1m) |

## Long-term Borrowings | (818.4m) | (1.1b) | (28.9m) | (17.0m) |

## Cash From Financing Activities | (473.2m) | (1.1b) | (115.6m) | (486.9m) |

## Net Change in Cash | (111.8m) | (104.2m) | 465.0m | 15.8m |

## Interest Paid | 19.9m | 30.1m | 19.9m | |

## Income Taxes Paid | 143.7m | 223.7m | 61.5m |

USD | FY, 2017 |
---|---|

## Debt/Equity | 0.4 x |

## Debt/Assets | 0.2 x |

## Financial Leverage | 1.9 x |